Fingerprint
Dive into the research topics of 'Risk classification and nivolumab plus ipilimumab combination therapy for treatment of renal cell carcinoma'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Risk classification and nivolumab plus ipilimumab combination therapy for treatment of renal cell carcinoma
Mototsugu Oya, Yohei Tajima, Koki Kabu
Research output: Contribution to journal › Review article › peer-review
1
Citation
(Scopus)